Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics (DFTX) reported positive Phase 3 results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. Shares have surged 12.88% in 7 days and 121.27% in 90 days, with a 1-year return of 391.80%. Analysts estimate revenue of $320.2M by July 2029 and a 1.7% profit margin, suggesting a 22.3% undervaluation at $46.18 vs. a $59.47 fair value.

Simply Wall St reports Definium Therapeutics (DFTX) shares fell about 5.6% after the company said its Phase 3 Voyage trial of DT120 ODT for generalized anxiety disorder met the primary and key secondary endpoints, with statistically significant HAM-A score reductions versus placebo and generally mild to moderate transient side effects. The article cites Q2 2026 net loss of $159.0M and $236.1M for 1H 2026.

Definium Therapeutics (DFTX) reported positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder, saying the study met its primary HAM-A endpoint and key secondary measures with generally well-tolerated safety and no new signals. The stock closed at $43.90. Analysts cite an average target of $67 and fair value of $59.47, with 2029 consensus revenue of $320.2M.

Definium Therapeutics (DFTX) shares rose about 9% after its Phase 3 Voyage trial reported that a single 100 µg dose of DT120 reduced anxiety symptoms in adults with generalized anxiety disorder versus placebo. The company said the HAM-A improvement was 11.6 points vs 6.2 at 12 weeks, with 43% vs 16% achieving at least 50% symptom reduction. Panorama Phase 3 results are expected in September.

Definium Therapeutics (Nasdaq: DFTX) shares rose up to 18% after the company reported positive top-line results from Voyage, its first Phase III study of DT120 (lysergide) ODT 100 µg for adults with generalized anxiety disorder. The readout follows earlier positive Phase III results for DT120 in major depressive disorder reported in June.

Definium Therapeutics (NASDAQ:DFTX) reported DT120 met Phase III goals in a GAD study. At week 1, HAM-A improved 11.9 points from baseline, 7.7 placebo-adjusted, with p<0.0001 at all time points. At week 12, remission was 14% vs 4% placebo; response 43% vs 16%. DT120 was generally well tolerated; no serious AEs or deaths in DT120.